Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients
暂无分享,去创建一个
A. Branch | T. Schiano | H. Te | J. Wiegel | Joseph C. Ahn | Coleman I. Smith | R. Satoskar | N. Patel | S. Robertazzi | Colleen Rodigas | Mohamed A. Hassan | D. Potosky | R. Kwok | Janet Gripshover | Amber Tierney | Michelle Lee Sang
[1] E. Schiff,et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence , 2016, Hepatology.
[2] E. Schiff,et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. , 2015, Gastroenterology.
[3] S. Pungpapong,et al. Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant , 2015, Hepatology.
[4] X. Forns,et al. An interferon-free antiviral regimen for HCV after liver transplantation. , 2014, The New England journal of medicine.
[5] G. Everson,et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. , 2014, Journal of hepatology.
[6] Robert Herring,et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.
[7] Stefan Zeuzem,et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[8] Sanjeev Arora,et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. , 2014, The New England journal of medicine.
[9] E. Schiff,et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. , 2013, The New England journal of medicine.
[10] A. Flaxman,et al. Global epidemiology of hepatitis C virus infection: New estimates of age‐specific antibody to HCV seroprevalence , 2013, Hepatology.
[11] W. Hohenberger,et al. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin. , 2011, Transplantation proceedings.
[12] K. Richardson,et al. Interferon‐Based Combination Anti‐Viral Therapy for Hepatitis C Virus After Liver Transplantation: A Review and Quantitative Analysis , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[13] J. Berlin,et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. , 2002, Gastroenterology.
[14] J. Mir,et al. Natural history of clinically compensated hepatitis C virus–related graft cirrhosis after liver transplantation , 2000, Hepatology.